Cargando…

A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting

BACKGROUND: Early detection of drug resistance is one of the priorities of tuberculosis (TB) control programs as drug resistance is increasing. New molecular assays are only accessible for a minority of the second line drugs and their availability in high endemic settings is also hampered by high co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wedajo, Wassihun, Schön, Thomas, Bedru, Ahmed, Kiros, Teklu, Hailu, Elena, Mebrahtu, Tesfamariam, Yamuah, Lawrence, Ängeby, Kristian, Werngren, Jim, Onyebujoh, Philip, Dagne, Kifle, Aseffa, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267144/
https://www.ncbi.nlm.nih.gov/pubmed/25108648
http://dx.doi.org/10.1186/1756-0500-7-512
_version_ 1782349108100464640
author Wedajo, Wassihun
Schön, Thomas
Bedru, Ahmed
Kiros, Teklu
Hailu, Elena
Mebrahtu, Tesfamariam
Yamuah, Lawrence
Ängeby, Kristian
Werngren, Jim
Onyebujoh, Philip
Dagne, Kifle
Aseffa, Abraham
author_facet Wedajo, Wassihun
Schön, Thomas
Bedru, Ahmed
Kiros, Teklu
Hailu, Elena
Mebrahtu, Tesfamariam
Yamuah, Lawrence
Ängeby, Kristian
Werngren, Jim
Onyebujoh, Philip
Dagne, Kifle
Aseffa, Abraham
author_sort Wedajo, Wassihun
collection PubMed
description BACKGROUND: Early detection of drug resistance is one of the priorities of tuberculosis (TB) control programs as drug resistance is increasing. New molecular assays are only accessible for a minority of the second line drugs and their availability in high endemic settings is also hampered by high cost and logistic challenges. Therefore, we evaluated a previously developed method for drug susceptibility testing (DST) including both first- and second line anti-TB drugs for use in high endemic areas. RESULTS: Baseline mycobacterial isolates from 78 consecutive pulmonary TB patients from Addis Ababa, Ethiopia who were culture positive for Mycobacterium tuberculosis at the end of a two-month directly observed treatment short course (DOTS) were included. The isolates were simultaneously tested for isoniazid, rifampicin, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide and para-aminosalicylic acid susceptibility using the indirect proportion method adopted for 24-well agar plates containing Middlebrook 7H10 medium. Applying the 24-well plate assay, 43 (55.1%) isolates were resistant to one or more of the first line drugs tested (isoniazid, rifampicin and ethambutol). MDR-TB was identified in 20.5% of this selected group and there was a perfect correlation for rifampicin resistance with the results from the genotype MTBDRplus assay. All isolates were susceptible to aminoglycosides and fluoroquinolones in agreement with the genotype MTBDRsl assay. The only tested second line drug associated to resistance was ethionamide (14.1% resistant). The method was reproducible with stable results for internal controls (one multi-drug resistant (MDR) and one pan-susceptible strain (H37Rv) and DST results could be reported at two weeks. CONCLUSIONS: The 24-well plate method for simultaneous DST for first- and second line drugs was found to be reproducible and correlated well to molecular drug susceptibility tests. It is likely to be useful in high-endemic areas for surveillance as well as for the detection of second line drug resistance in targeted groups such as in those who fail empirical MDR treatment.
format Online
Article
Text
id pubmed-4267144
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42671442014-12-17 A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting Wedajo, Wassihun Schön, Thomas Bedru, Ahmed Kiros, Teklu Hailu, Elena Mebrahtu, Tesfamariam Yamuah, Lawrence Ängeby, Kristian Werngren, Jim Onyebujoh, Philip Dagne, Kifle Aseffa, Abraham BMC Res Notes Research Article BACKGROUND: Early detection of drug resistance is one of the priorities of tuberculosis (TB) control programs as drug resistance is increasing. New molecular assays are only accessible for a minority of the second line drugs and their availability in high endemic settings is also hampered by high cost and logistic challenges. Therefore, we evaluated a previously developed method for drug susceptibility testing (DST) including both first- and second line anti-TB drugs for use in high endemic areas. RESULTS: Baseline mycobacterial isolates from 78 consecutive pulmonary TB patients from Addis Ababa, Ethiopia who were culture positive for Mycobacterium tuberculosis at the end of a two-month directly observed treatment short course (DOTS) were included. The isolates were simultaneously tested for isoniazid, rifampicin, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide and para-aminosalicylic acid susceptibility using the indirect proportion method adopted for 24-well agar plates containing Middlebrook 7H10 medium. Applying the 24-well plate assay, 43 (55.1%) isolates were resistant to one or more of the first line drugs tested (isoniazid, rifampicin and ethambutol). MDR-TB was identified in 20.5% of this selected group and there was a perfect correlation for rifampicin resistance with the results from the genotype MTBDRplus assay. All isolates were susceptible to aminoglycosides and fluoroquinolones in agreement with the genotype MTBDRsl assay. The only tested second line drug associated to resistance was ethionamide (14.1% resistant). The method was reproducible with stable results for internal controls (one multi-drug resistant (MDR) and one pan-susceptible strain (H37Rv) and DST results could be reported at two weeks. CONCLUSIONS: The 24-well plate method for simultaneous DST for first- and second line drugs was found to be reproducible and correlated well to molecular drug susceptibility tests. It is likely to be useful in high-endemic areas for surveillance as well as for the detection of second line drug resistance in targeted groups such as in those who fail empirical MDR treatment. BioMed Central 2014-08-10 /pmc/articles/PMC4267144/ /pubmed/25108648 http://dx.doi.org/10.1186/1756-0500-7-512 Text en © Wedajo et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wedajo, Wassihun
Schön, Thomas
Bedru, Ahmed
Kiros, Teklu
Hailu, Elena
Mebrahtu, Tesfamariam
Yamuah, Lawrence
Ängeby, Kristian
Werngren, Jim
Onyebujoh, Philip
Dagne, Kifle
Aseffa, Abraham
A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting
title A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting
title_full A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting
title_fullStr A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting
title_full_unstemmed A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting
title_short A 24-well plate assay for simultaneous testing of first and second line drugs against Mycobacterium tuberculosis in a high endemic setting
title_sort 24-well plate assay for simultaneous testing of first and second line drugs against mycobacterium tuberculosis in a high endemic setting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267144/
https://www.ncbi.nlm.nih.gov/pubmed/25108648
http://dx.doi.org/10.1186/1756-0500-7-512
work_keys_str_mv AT wedajowassihun a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT schonthomas a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT bedruahmed a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT kirosteklu a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT hailuelena a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT mebrahtutesfamariam a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT yamuahlawrence a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT angebykristian a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT werngrenjim a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT onyebujohphilip a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT dagnekifle a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT aseffaabraham a24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT wedajowassihun 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT schonthomas 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT bedruahmed 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT kirosteklu 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT hailuelena 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT mebrahtutesfamariam 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT yamuahlawrence 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT angebykristian 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT werngrenjim 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT onyebujohphilip 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT dagnekifle 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting
AT aseffaabraham 24wellplateassayforsimultaneoustestingoffirstandsecondlinedrugsagainstmycobacteriumtuberculosisinahighendemicsetting